The first coronavirus vaccine developed in India called Covaxin is “highly effective” and poses no safety risk.
This follows from a study that was published in a prestigious professional journal The Lancet, AFP reported.
The Covaxin vaccine was developed by the Indian company Bharat Biotech in collaboration with the Indian Board of Health Research. It has already been approved in 17 countries around the world, and last week the World Health Organization (WHO) also approved its emergency use.Read also A retiree discovered a new species of dinosaur sorting fossil boxes
According to the WHO, the vaccine is 78 percent effective one month after its second dose.
According to a study published in The Lancet, Covaxin is “highly effective against laboratory-confirmed symptomatic COVID-19 in adults.” In addition, the vaccine “does not raise any safety concerns in the preliminary analysis”.
The WHO described the vaccine as “particularly suitable for low- and middle-income countries due to its low storage conditions”. Indeed, some covid vaccines require storage at very low temperatures, creating logistical problems and increased financial costs.Read also The antiviral for the treatment of covid has been shown to be highly effective
The Indian vaccine could “increase global vaccine production capacity and help address the shortage of vaccine supplies that are disproportionately affecting low- and middle-income countries,” said Chinese researchers Li Jingsin Li and Zhu Fenghai, who participated in a study published in The Lancet.
However, both also pointed to some shortcomings in the testing of Covaxin: according to them, clinical trials were conducted only in India itself, and the group of people studied was thus not very diverse from an ethnic point of view.Read also Delta plus has already been confirmed in Slovakia
In addition, this study was conducted between November 2020 and January 2021, at a time when the world was not yet dominated by the highly contagious delta variant. However, the researchers were able to verify that Covaxin also provides protection against this variant, although it is slightly less effective in this case.
Source: Pravda – Veda a technika by vat.pravda.sk.
*The article has been translated based on the content of Pravda – Veda a technika by vat.pravda.sk. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!